Celldex Therapeutics (NASDAQ: CLDX)
Celldex Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Celldex Therapeutics Company Info
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
News & Analysis
Why Celldex Therapeutics Blasted 13% Higher on Monday
The biotech's CSU treatment advanced in the laboratory.
How Good Were Celldex Therapeutics' Latest Clinical Results?
The short answer: impressive.
Why Celldex Therapeutics Stock Is Jumping Again Today
The company announced a public stock offering.
Why Celldex Therapeutics Stock Is Skyrocketing Today
Investors liked Celldex's early stage clinical results.
Could Celldex Be a Millionaire-Maker Stock?
Not at its present valuation, it's not.
Why Celldex Therapeutics Stock Is Tanking Today
The biotech reported interim results from a phase 1b study.
3 Healthcare Stocks That Surged Last Week
Here's what pushed up shares of the highest-flying healthcare stocks.
Here's Why Celldex Therapeutics Stock Is Soaring Today
The market is reacting to large stock purchases from inside and outside the company.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.